

Short Research Article

Levels of oxidized low-density lipoprotein and high sensitive C-reactive protein in retinal vascular occlusions: a pilot study

ABSTRACT

BACKGROUND

Oxidized low-density lipoprotein (OX-LDL) is believed to be a key trigger factor in the genesis of atherosclerosis. It has been postulated that it can activate inflammatory mediators such as high sensitive C-reactive protein (hs-CRP), interleukin 6 (IL6), and tumour necrosis factor (TNF). These mediators have been demonstrated to have an atherogenic effect.

AIMS

This pilot study examined levels of OX-LDL and hs-CRP in patients with retinal vascular occlusive disorders.

METHODS

We enrolled 7 patients with retinal vascular occlusions during a two-month period. A high sensitive CRP of greater than 3mg/l was considered significantly elevated and a median oxidised LDL value greater than 59 U/L was considered significantly elevated.

RESULTS

There were 4 cases of retinal vein occlusion, 1 case of amaurosis fugax, 1 case of cilioretinal artery occlusion and a case of cholesterol embolus in the retinal vasculature. Mean OX-LDL (55.6 ± 21.1 U/L) and hs-CRP (3.9 ± 3.1 mg/l) were elevated compared to controls (36.0 ± 0.0 U/L, students t-test $p = 0.252$ and 2.0 ± 1.9 mg/l, students t-test $p = 0.431$, respectively). Oxidized LDL was elevated in three patients (43%), and borderline (between 55 and 59 U/L) in two patients (28%). No significant correlation was found between hs-CRP and OX-LDL values (Pearson's correlation: $r = 0.256$; $p = 0.456$).

CONCLUSIONS

This study is the first to suggest that OX-LDL and hs-CRP may be elevated in retinal vascular disease. Further investigations are required to determine the significance of these findings

Introduction

Retinal vascular occlusive diseases include a spectrum of clinical conditions such as, retinal venous occlusion (branch, hemiretinal or central), retinal arterial occlusion (branch or central) and transient occlusive events (amaurosis fugax). There are several different mechanisms by which these different clinical scenarios may occur and thus many varied risk factors have been implicated in the aetiology of retinal vascular occlusions. These risk factors include factors in the wall of the vessels, factors affecting flow through the vessels and variations of the constituents of the blood flowing through the vessel, collectively known as Virchow's triad.[1] The risk factor common to all forms of retinal vascular disease is atherosclerosis, which may lead to thrombotic and/or embolic events that may transiently or permanently occlude a retinal artery, causing amaurosis fugax or retinal artery occlusion, respectively. Atherosclerosis is also the most common underlying cause of retinal vascular occlusions.[2]

Recently, research has focused upon subcategories of low-density lipoprotein (LDL) in the context of atherosclerosis. It has been shown that a subtype of LDL termed oxidized (Ox-LDL) has a strong predictive role for the presence of vascular atherosclerosis.[3]

Inflammation has been implicated to play a pivotal role in all phases of atherosclerosis, from the fatty streak lesion formation to the acute coronary event due to vulnerable plaque rupture. There is evidence that vascular inflammation contributes to the pathogenesis of atherosclerosis, and later in the disease process, it is a major determinant for the acute coronary syndromes. High-sensitive C-reactive protein (hs-CRP), a simple downstream marker of inflammation, is a plasma protein synthesised by the liver. In the absence of large inflammatory spikes, the year-to-year within person variations in hs-CRP concentration are similar to those in total cholesterol concentration and systolic blood pressure. In a literature-based meta-analysis of 22 prospective studies, the relative risk for coronary heart disease was 1.6 (95% CI 1.5–1.7) in a comparison of people in the top third (mean 2.4 mg/L) and bottom third (1.0 mg/L) of the hs-CRP distribution.[4]

Elevated baseline concentrations of hs-CRP are associated with the risk of atherosclerotic events in general populations and show a predictive value even in terms of secondary prevention, both in patients with chronic stable angina and acute coronary syndromes.[5]

To date there has been no published data regarding a possible link between either Ox-LDL or hs-CRP and retinal vascular occlusive disorders. The purpose of our study is to evaluate if such a possible link exists.

Patients and Methods

We present a pilot study of patients with retinal vascular occlusions (retinal venous occlusion, retinal arterial occlusion or amaurosis fugax), enrolled during a two-month period. Patients gave informed consent and this study adhered to the tenets of the declaration of Helsinki. Local ethics committee approval was obtained.

All patients underwent a dilated ophthalmic biomicroscopic examination. In addition to routine serological investigations we performed analysis of fasting LDL, Ox-LDL and hs-CRP. Ten eyes in 10 patients had retinal vascular pathology during the study period. Patients who were already

taking acetylsalicylic acid and statins (HMG-CoA reductase inhibitors, $n = 3$) were excluded as these medications have been shown to reduce the levels of circulating oxidized LDL and hs-CRP.[6,7] Patients with any evidence of intercurrent infection ($n = 0$) were also excluded, as this can alter hs-CRP levels.[8] The seven patients who remained were included in the analysis.

Analysis of hs-CRP was performed with a Beckman Immage immunochemistry system (Beckmann Coulter, Brea, CA, USA), using Beckman hs-CRP reagent for the quantitative determination of hs-CRP in serum or plasma by rate turbidimetry. A value for hs-CRP of greater than 3mg/l was considered significantly elevated.

OX-LDL analysis was carried out using an enzyme linked immunosorbent assay kit (ELISA; Mercodia AB, Uppsalla, Sweden). In this assay oxidized LDL levels were measured by competitive ELISA utilising a specific murine monoclonal antibody mAB -4E6. The Mercodia kit is a capture ELISA in which wells of the microplate are coated with a capture antibody. A median value greater than 59 U/L was considered significantly elevated. OX-LDL is a very complicated particle, a number of epitopes exist, the method described in this study detects the epitope particular to the apolipoprotein B-100 moiety of LDL. Mercodia OX-LDL ELISA is a solid phase two-site enzyme immunoassay. It is based on the direct sandwich technique in which two monoclonal antibodies are directed against separate antigenic determinants on the oxidized apolipoprotein B molecule.

Mean values were compared using a students t-test, correlations were performed utilizing Pearsons Coefficient, a p value of < 0.05 was taken as statistically significant.

Results

We present the analysis of 7 patients with retinal vascular occlusions. There were four male patients (57%) and three female patients (43%). There were 3 (43%) cases of central retinal vein occlusion (CRVO), 2 (29%) cases of amaurosis fugax, 1 (14%) case of cilioretinal artery occlusion and a case (14%) of branch retinal artery occlusion (BRAO) secondary to a cholesterol embolus in the retinal vasculature. We also present 2 controls (both male), who were members of staff with no ocular pathology. Only three of the patients (43%) had underlying systemic risk factors for atherosclerotic disease namely: hypertension, diabetes and hypercholesterolemia.

The mean age ($\pm$ standard deviation, SD) of the patients was 61.0 ($\pm$ 16.0) years, this was not significantly larger than the mean age of the controls (40.0 $\pm$ 7.1 years; 2 tailed, independent samples t-test: $p = 0.125$). The mean LDL, OX-LDL and hs-CRP ($\pm$ SD) for all patients, only those with no comorbidity and controls are displayed in table 1.

Four patients (57%) had hs-CRP levels above the upper limit of normal (3mg/l), one of the controls had a hs-CRP over 3 mg/l (Table 2). Two of the patients had elevated LDL levels (normal reference range: 2.5 – 3.5 mmol/L). Four patients (57%) had an LDL level (≥ 3.0 mmol/L) above the advised level for moderate risk patients,[9] while both controls (100%) had LDL levels within the normal reference range. With regard to OX-LDL levels, three patients (43%) had elevated levels, while both controls (100%) had normal levels.

LDL was not significantly correlated with OX-LDL (Pearson's correlation: $r = 0.67$; $p = 0.565$), nor did OX-LDL levels not show a significant correlation with hs-CRP (Pearson's correlation: r

= 0.256; p = 0.456). Age was not significantly correlated with LDL, OX-LDL or hs-CRP (Pearson's correlation: r = -0.237; p = 0.538, r = 0.121; p = 0.756, and r = 0.294; p = 0.442, respectively).

Discussion

Holovet et al. found significantly elevated mean levels of OX-LDL and LDL in patients with atherosclerotic coronary artery disease. Patients had 139% higher mean OX-LDL and 10% higher mean LDL, when compared to controls.[10] A study of patients with atherosclerotic peripheral vascular disease, found 20% higher mean OX-LDL levels and 26% higher mean LDL levels, compared to controls.[11] Our study found 54% higher mean OX-LDL levels and 3% higher mean LDL in patients with retinal vascular occlusions, compared to controls. While there is considerable variation regarding the overall figures between these studies, they do reflect a general trend towards increased OX-LDL and LDL levels in the context of atherosclerotic disorders.

Patients with high hs-CRP concentrations are more likely to develop stroke, MI and significant peripheral vascular disease.[4] Mean levels of hs-CRP have been reported to be significantly higher in patients with acute ischaemic stroke (4.87 mg/l for patients and 0.99 mg/l for controls),[12] acute myocardial infarction (2.7 mg/l for patients and 1.0 for controls),[13] and peripheral vascular disease (3.4 mg/l for patients).[14] Our study suggests a similar level of elevation in hs-CRP is associated with retinal vascular occlusions. It is interesting to note that the three parameters of mean hs-CRP, LDL and OX-LDL were even higher in our study when patients with comorbidities were excluded.

It is interesting to examine the evidence regarding these parameters (hs-CRP and OX-LDL) in the context of other ophthalmology disorders. OX-LDL[15] and CRP[16] have both been reported to be significantly higher in patients with neovascular age related macular degeneration (AMD). Atherosclerosis has previously been implicated in the aetiology of this disease.[15] None of our patients or controls had any evidence of AMD.

The small number of patients and controls with the heterogeneity of the pathology are obvious limitations to this study. We acknowledge that the individual retinal vascular disorders have very different underlying proposed mechanisms and this limits the interpretation of our results. However, this is the first report of a possible trend towards higher mean levels of hs-CRP and Ox-LDL in patients with retinal vascular occlusions. This pilot study supports the case for larger prospective studies to elucidate the exact nature of these potential relationships and investigate their clinical significance.

Conclusion

This pilot study suggests a trend of increase levels of OX-LDL and hs-CRP may potentially occur in the context of retinal vascular occlusive disorders.

146 **Competing interests:**

147 The Authors have no competing interests in this study.

148

149 **References**

- 150 1. Bennett PC, Silverman SH, Gill PS, Lip GY (2009) Peripheral arterial
151 disease and Virchow's triad. *Thrombosis and haemostasis* 101 (6):1032-1040
- 152 2. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ
153 (2005) Retinal vein occlusion: a form of venous thrombosis or a complication
154 of atherosclerosis? A meta-analysis of thrombophilic factors. *Thrombosis and*
155 *haemostasis* 93 (6):1021-1026. doi:10.1267/THRO05061021
- 156 3. Rizzo M, Berneis K, Koulouris S, Pastromas S, Rini GB, Sakellariou D, et
157 al. (2010) Should we measure routinely oxidised and atherogenic dense low-
158 density lipoproteins in subjects with type 2 diabetes? *International journal of*
159 *clinical practice* 64 (12):1632-1642. doi:10.1111/j.1742-1241.2010.02378.x
- 160 4. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys
161 MB, Thompson SG, Collins R, et al. (2010) C-reactive protein concentration
162 and risk of coronary heart disease, stroke, and mortality: an individual
163 participant meta-analysis. *Lancet* 375 (9709):132-140. doi:10.1016/S0140-
164 6736(09)61717-7
- 165 5. Calabro P, Golia E, Yeh ET (2009) CRP and the risk of atherosclerotic
166 events. *Seminars in immunopathology* 31 (1):79-94. doi:10.1007/s00281-009-
167 0149-4
- 168 6. Yang H, Mohamed AS, Zhou SH (2012) Oxidized low density lipoprotein,
169 stem cells, and atherosclerosis. *Lipids in health and disease* 11:85.
170 doi:10.1186/1476-511X-11-85
- 171 7. Deng J, Wu Q, Liao Y, Huo D, Yang Z (2012) Effect of statins on chronic
172 inflammation and nutrition status in renal dialysis patients: a systematic review
173 and meta-analysis. *Nephrology* 17 (6):545-551. doi:10.1111/j.1440-
174 1797.2012.01597.x
- 175 8. Meguro S, Ishibashi M, Takei I (2012) [The significance of high sensitive C
176 reactive protein as a risk factor for cardiovascular diseases]. *Rinsho byori The*
177 *Japanese journal of clinical pathology* 60 (4):356-361
- 178 9. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O,
179 et al. Clinical Practice Guidelines Committee of the Spanish Society of C
180 (2011) [ESC/EAS Guidelines for the management of dyslipidaemias]. *Revista*
181 *espanola de cardiologia* 64 (12):1168 e1161-1168 e1160.
182 doi:10.1016/j.recesp.2011.09.014
- 183 10. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe
184 R, et al. (2001) Circulating oxidized LDL is a useful marker for identifying
185 patients with coronary artery disease. *Arteriosclerosis, thrombosis, and*
186 *vascular biology* 21 (5):844-848
- 187 11. Andican G, Seven A, Uncu M, Cantasdemir M, Numan F, Burcak G (2008)
188 Oxidized LDL and anti-oxLDL antibody levels in peripheral atherosclerotic
189 disease. *Scandinavian journal of clinical and laboratory investigation* 68
190 (6):473-478. doi:10.1080/00365510701842996
- 191 12. Yeh KH, Tsai TH, Chai HT, Leu S, Chung SY, Chua S, et al.(2012)
192 Comparison of acute versus convalescent stage high-sensitivity C-Reactive
193 protein level in predicting clinical outcome after acute ischemic stroke and

194 impact of erythropoietin. Journal of translational medicine 10:6.
 195 doi:10.1186/1479-5876-10-6
 196 13. Rashidinejad H, Hosseini SM, Moazenzadeh M, Azimzadeh BS,
 197 Mirzaeipour F, Fakhreddini K, et al. (2012) Relationship between serum level
 198 of high-sensitive C-reactive protein and extension of myocardial involvement
 199 in patients with acute myocardial infarction. Romanian journal of internal
 200 medicine = Revue roumaine de medecine interne 50 (3):211-215
 201 14. Cassar K, Ford I, Greaves M, Bachoo P, Brittenden J (2005) Randomized
 202 clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus
 203 aspirin alone after lower limb angioplasty. The British journal of surgery 92
 204 (2):159-165. doi:10.1002/bjs.4810
 205 15. Ikeda T (2003) [The pathogenesis of vitreoretinal diseases from the
 206 standpoint of molecular biology]. Nippon Ganka Gakkai zasshi 107 (12):785-
 207 812
 208 16. Colak E, Majkic-Singh N, Zoric L, Radosavljevic A, Kosanovic-Jakovic N
 209 (2012) The role of CRP and inflammation in the pathogenesis of age-related
 210 macular degeneration. Biochemia medica 22 (1):39-48
 211
 212

213

	All Patients (n = 7)	Controls (n = 2)	Patients without comorbidity (n = 4)	P value
Hs-CRP (mg/l)	3.9 ± 3.1	2.0 ± 1.9	4.7 ± 3.4	0.431; 0.354
LDL (mmol/l)	3.1 ± 0.7	3.1 ± 0.1	3.6 ± 0.5	0.868; 0.121
OX-LDL (U/L)	55.6 ± 21.1	36.0 ± 0.0	58.3 ± 28.3	0.252; 0.354

215 **Table 1.**

216 Table displaying the mean ($\pm$ standard deviation) parameters of three defined groups. All patients: all
 217 study patients with retinal vascular occlusion. Controls: healthy control subjects. Patients without
 218 comorbidity: retinal vascular occlusion patients with no documented cardiovascular comorbidity. Hs-
 219 CRP: high sensitive C-reactive protein. LDL: low-density lipoprotein. OX-LDL: oxidized low-density
 220 lipoprotein. P value: levels of significance from independent samples t-tests. First p value in column
 221 relates to analyses between all patients and controls, second p value relates to analyses between
 222 patients without comorbidity and controls.

223

Patient	Age	Sex	Diagnosis	Hs-CRP (mg/l)	LDL (mmols/l)	Ox LDL (u/l)	Systemic condition
1	33	F	CRVO	4.14	4.0	79	-
2	75	M	Cilioret art occl	1.97	3.1	79	-
3	81	F	Am fugax	6.08	2.9	62	DM, chol
4	51	F	Am fugax	3.27	3.2	56	-
5	65	M	Chol embolus	0.86	2.9	52	DM, HTN
6	65	M	CRVO	9.61	4.0	19	-
7	57	M	CRVO	1.57	1.9	42	HTN
Ctrl 1	45	M	-	3.30	3.0	36	-
Ctrl 2	35	M	-	0.64	3.1	36	-

224 Table showing the individual patients demographics, age, sex, retinal diagnosis, levels
 225 of High-sensitive C-reactive protein (HS-CRP), low density lipoprotein (LDL),
 226 oxidized LDL and any systemic illnesses with cardiovascular implications. Column
 227 one relates to the patient or control (Ctrl) number. Abbreviations: F- female, M- Male,
 228 CRVO- central retinal vein occlusion, cilioret art occl- Cilioretinal artery occlusion,
 229 Am fugax- Amaurosis fugax, Chol embolus- cholesterol embolus, DM- diabetes
 230 mellitus (type 2 in both cases), Chol- hypercholesterolaemia, HTN- hypertension.